Pivotal data supports U.S. FDA De Novo clearance and sets the stage for U.S. launch GALWAY, Ireland--(BUSINESS WIRE)-- Signum Surgical, a medical technology company dedicated to advancing the ...
The U.S. FDA granted Signum Surgical Ltd. de novo marketing clearance for its Biohealx technology as a treatment for anal fistula. Biohealx is a single use, bioabsorbable implant, designed to not only ...
A consortium of University of Birmingham researchers, clinicians and industry partners is developing a novel device that could revolutionize the clinical management of anal fistula. In this intrusive ...
A consortium of Birmingham researchers, clinicians and industry partners has received a second £1.1m award from the National Institute for Health and Care Research (NIHR) for a three-year study ...
- Medtech expert to drive commercialization of BioHealx ® for the treatment of anal fistula. GALWAY, Ireland--(BUSINESS WIRE)--Signum Surgical, (‘Signum’ or ‘the Company’) the medical technology ...
STATEN ISLAND, N.Y. -- Northwell Staten Island University Hospital has become the first U.S. medical center to perform surgery using BioHealx, a new FDA-approved anal fistula device Dr. Poppy Addison ...
Northwell's Staten Island University Hospital (SIUH) is the first medical center in the United States to perform surgery using the newly FDA-cleared BioHealx (R)Anal Fistula Device - offering new hope ...
Signum Surgical, a medical technology company dedicated to advancing the treatment of colorectal diseases, today announced the publication of first-in-human clinical data for its BioHealx® Anal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results